Julius N. Korley, Ph.D., is associate vice president for the University of Delaware's Office of Economic Innovation and Partnerships (OEIP). A unit of the Research Office, OEIP serves as the University’s gateway for connecting faculty innovators and entrepreneurs with potential collaborators outside UD for the benefit of society.
Korley is a businessperson, entrepreneur and scientist with expertise in several areas of biotechnology, including biomaterials, drugs, drug-delivery systems and medical device development. Korley is also a member of the national faculty for I-Corps at the National Institutes of Health.
Prior to UD, Dr. Korley served as the Associate Director of the Case-Coulter Translational Research Partnership at Case Western Reserve University (CWRU). This position focused on translational medicine and the commercialization of laboratory technologies that address unmet or poorly met human healthcare needs. In this role, Dr. Korley oversaw more than 70 technologies leading to more $75M in follow-on funding, 13 licensed technologies, 11 startups and 16 technolgies in humans.
Dr. Korley also co-founded the biomedical engineering company Affinity Therapeutics and has successfully helped the company raise all non-dilutive funding to date. He has extensive experience in fundraising, business development, strategic partnering and licensing activities and was named Affinity’s inaugural President and CEO in August of 2015.
Prior to co-founding Affinity and joining CWRU, Dr. Korley first worked at Momenta Pharmaceuticals (MNTA), a then startup. In October of 2020, Momenta was acquired by Johnson & Johnson. Dr. Korley earned a Ph.D. at Cornell University and an MBA at the Weatherhead School of Management at CWRU.